Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?

Amid its sputtering launch, Biogen expects to receive a draft decision on Aduhelm’s coverage on Medicare next week. Industry watchers have been calculating a range of potential scenarios, but whichever direction the ruling goes, doctor feedback suggests it may simply not matter that much.